Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tandem Diabetes Care Inc.

www.tandemdiabetes.com

Latest From Tandem Diabetes Care Inc.

Senseonics, TypeZero Join Forces On Artificial Pancreas

Diabetes companies Senseonics and TypeZero Technologies have signed a research and development licensing agreement to develop an artificial pancreas.

Metabolic Disorders Diabetic Care

Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.

Diabetic Care Metabolic

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical

Medtronic Artificial Pancreas Trial Results Published

Medtronic’s Hybrid closed-loop system is safe and improves some key patient outcomes, according to results published in the Journal of the American Medical Association. The system is currently before FDA for review.

Research & Development Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tandem Diabetes Care Inc.
  • Senior Management
  • Kim Blickenstaff, Pres. & CEO
    John Cajigas, CFO
    Brian Hansen, EVP, Chief Commercial Officer
    Mike Rosinko, VP, R&D
  • Contact Info
  • Tandem Diabetes Care Inc.
    Phone: (858) 366-6900
    11045 Roselle St., Ste. 200
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register